[Victoza changes diabetes and lives of patients 5 years already]. Victoza (liraglutide) is a modern antidiabetic drug of GLP1 (glucagone like peptide) analogue group; since 2009 registered in Czech republic.  VICTOZA is used in therapy of type 2 diabetic patients with preserved endougenous insulin secretion, usually in combination with other peroral antidiabetic drugs or with basal insulin.  VICTOZA is applied once a day subcutaneously.  Alltogether, VICTOZA is a well tolerated antidiabetic medication decreasing glycated hemoglobin up to 15 mmol/l with minimal risk of hypoglycaemia.
Victoza
[Victoza changes diabetes and lives of patients 5 years already]. Victoza (liraglutide) is a modern antidiabetic drug of GLP1 (glucagone like peptide) analogue group; since 2009 registered in Czech republic.  VICTOZA is used in therapy of type 2 diabetic patients with preserved endougenous insulin secretion, usually in combination with other peroral antidiabetic drugs or with basal insulin.  VICTOZA is applied once a day subcutaneously.  Alltogether, VICTOZA is a well tolerated antidiabetic medication decreasing glycated hemoglobin up to 15 mmol/l with minimal risk of hypoglycaemia.
VICTOZA
Victoza (liraglutide) is a modern antidiabetic drug of GLP1 (glucagone like peptide) analogue group; since 2009 registered in Czech republic. 
GLP1
Victoza (liraglutide) is a modern antidiabetic drug of GLP1 (glucagone like peptide) analogue group; since 2009 registered in Czech republic. 
liraglutide
Victoza (liraglutide) is a modern antidiabetic drug of GLP1 (glucagone like peptide) analogue group; since 2009 registered in Czech republic. 
Czech republic
VICTOZA is applied once a day subcutaneously. 
subcutaneously
The characteristical antidiabetic effect with β cell protection is enhanced with supportive weigth reduction effect. 
β cell protection